GlaxoSmithKline LLC, Durham, North Carolina (SPE2DP-22-D-0002, $33,803,616); and Seqirus Inc., Summit, New Jersey (SPE2DP-22-D-0003, $8,636,345), have each been awarded a firm-fixed-price, indefinite-quantity contract under solicitation SPE2DP-21-R-0131 for the injectable influenza vaccine. This was a competitive acquisition with four responses received. These are one-year contracts with no option periods. Locations of performance are Pennsylvania, New Jersey and North Carolina, with a Feb. 24, 2023, ordering period end date. Using customers are Army, Air Force, Navy, Marine Corps and Coast Guard. Type of appropriation is fiscal 2022 through 2023 defense working capital funds. The contracting activity is the Defense Logistics Agency Troop Support, Philadelphia, Pennsylvania.